Why is the orphan-drug carveout in Medicare pricing facing scrutiny?

A new analysis highlighted by STAT News on August 4, 2026 argues the federal exemption shielding some orphan drugs from Medicare price negotiations may no longer be justified. The debate matters because the carveout affects drugmakers’ pricing and indication strategies and could become a broader policy fight over which drugs stay outside negotiation.